The BioFINDER Steering Group

Prof Oskar Hansson

Principal Investigator

Professor and Senior Neurologist at the Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University and at the Memory Clinic, Skåne University Hospital. Dr Hansson’s overriding aim is to combine clinical work with innovative research to help patients suffering from neurodegenerative disorders, mainly Alzheimer’s and Parkinson’s diseases. He has funded all his research through significant independent grants from e.g. the European Research Council (ERC) and the Swedish Research Council. His work is widely recognized with papers in e.g. Lancet Neurology and JAMA. His work on biomarkers has influenced the newly proposed diagnostic criteria for Alzheimer’s disease. Dr Hansson is part of and in leading positions in several distinguished scientific networks, including the strategic network in neuroscience at Lund University (MultiPark), Swedish Parkinson Academy, and Swedish Brain Power.

Dr Erik Stomrud

Logistics and clinical assessment

Dr Stomrud is responsible for the logistics of BioFINDER, especially in the cohort with cognitively healthy elderly participants. His overriding research aim is to understand the mechanisms of healthy aging and differentiate it from neurocognitive disorders.


Sebastian porträttAssoc Prof Sebastian Palmqvist

Clinical assessment and cognitive testing

Dr Palmqvist’s focus lies on the clinical evaluation and follow-up of the patients with mild cognitive symptoms. He is interested in the association between disease mechanisms and  clinical symptoms of the patients. Other interests include early biomarkers and cognitive testing. Aside from his research in BioFINDER, dr Palmqvist works clinically at the department of Neurology (Skåne University Hospital, Sweden).


niklasAssoc Prof Niklas Mattsson

Blood and CSF biomarkers

Dr Mattsson’s main research interest is Alzheimer’s disease, where he uses biochemical markers to improve methods for diagnosis and prognosis, inform design of clinical trials, and gain novel understanding of disease mechanisms. He is particularly interested in the importance of different pathological changes during the very early stages of Alzheimer’s disease. He shares his time between research and a neurology residency, and he is also a board-certified specialist in clinical chemistry.




Dr Smith’s main interest is to identify different disease mechanisms using PET to understand the different underlying pathologies of neurocognitive disorders. Since baseline,  18F-Flutemetamol (β-amyloid) has been used within the BioFINDER study, but we are now  expanding the number of  radiotracers. As January 2017 we are also scanning included patients with 18F-AV-1451 (tau) and 18F-FDG-PET scans. In the upcoming BioFINDER 2 study we will also include 18F-RO6958948 (tau) PET in the scanning protocol and add three high resolution digital GE Discovery MI PET/CT scanners.


Assoc Prof Rik Ossenkoppele


Dr. Ossenkoppele uses various neuroimaging techniques (PET: Tau, Aβ, glucose metabolism; MRI: brain atrophy and functional connectivity) to study the Alzheimer’s disease spectrum, with a specific focus on disease heterogeneity, progression and brain resilience. His research is aimed at gaining a better understanding of disease mechanisms Alzheimer’s disease and at optimizing diagnostic and prognostic neuroimaging markers for clinical use. He shares his research time between the Swedish BioFINDER study group and the VUMC Alzheimercenter in Amsterdam.


Assoc Prof Danielle van Westen


Dr van Westen is a senior neuroradiologist at Skåne University Hospital in Sweden. Her interests include the associations between radiological biomarkers and clinical phenotypes as well as methodological aspects of MRI.


The BioFINDER Study Group and Collaborators

Located in Sweden if not otherwise specified.

Clinical Memory Research Unit, Lund University

Emelie Andersson, PhD student

David Berron, PhD

Alexa Pichet Binette, PhD

Elin Byman, PhD student

Emma Borland, MD PhD student

Anna Callmer, MD

Cecilia Dahl, RN

Eske Gertje, MD PhD student

Isabelle Glans, MD PhD student

Anna-Märta Gustavsson, MD PhD student

Joanna Grzegorska, Administrator

Sara Hall, MD PhD

Oskar Hansson, MD PhD, Head of the research group

Philip Insel, PhD

Shorena Janelidze, PhD

Maurits Johansson, MD

Helena Sletten, MD

Jonas Jester-Broms, MD

Elisabet Londos, MD PhD

Niklas Mattson, MD PhD

Lennart Minthon, MD PhD

Maria Nilsson, PhD

Katarina Nägga, MD PhD

Camilla Orbjörn, MLT

Rik Ossenkoppele, PhD

Sebastian Palmqvist, MD PhD

Marie Persson, RN

Anne-Marie Rohrstock, Administrator

Gemma Salvado Blasco, PhD

Alexander Santillo, MD PhD

Nicola Spotorno, PhD

Erik Stomrud, MD PhD

Anna Svenningsson, MD PhD student

Håkan Toresson, PhD

Olof Strandberg, QMP

Memory Clinic, Ängelholm Hospital

Ida Friberg, RN

Per Johansson, MD PhD

Moa Wibom, MD

Department of Neurology, Skåne University Hospital

Katarina Johansson, RN

Emma Pettersson, RN

Christin Karremo, RN

Ruben Smith, MD PhD

Department of Neurosurgery, Skåne University Hospital

Mattis Jalakas, MD PhD student

MRI unit, Lund University

Linda Knutsson, PhD

Jimmy Lätt, QMP

Peter Mannfolk, PhD

Markus Nilsson, PhD

Freddy Ståhlberg, MD PhD

Pia Sundgren, MD PhD

Danielle van Westen, MD PhD

Clinical Neurochemistry Laboratory, University of Gothenburg

Ulf Andreasson, PhD

Kaj Blennow, MD PhD

Henrik Zetterberg, MD PhD

MRI unit, Karolinska Institutet

Lars-Olof Wahlund, MD PhD

Eric Westman, PhD

Joana Pereira, PhD

PET unit, Lund University

Jonas Jögi, MD PhD

Douglas Hägerström, MD

Tomas Olsson, QMP

Per Wollmer, MD PhD

Developmental and Regenerative Neurobiology, Lund University

Malin Parmar PhD

Ulrich Pfisterer PhD

Other collaborators

GE Healthcare, USA ([18]F-flutemetamol doses for amyloid PET)

AVID/Lilly, USA ([18]F-T807 doses for Tau PET)

Roche, Switzerland ([18]F-RO948 doses for Tau PET)